FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.
The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.

Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

Lundbeck, Otsuka's Rexulti wins FDA nod for Alzheimer's agitation

FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia Due to Alzheimer's Disease

SLU Researcher Finds Help for Alzheimer's-Associated Agitation with New FDA- Approved Treatment : SLU

Researcher finds help for Alzheimer's-associated agitation with new FDA- approved treatment

FDA Approves Rexulti for Agitation Associated With Dementia Due to Alzheimer's Disease

REXULTI® (brexpiprazole) For Healthcare Professionals

FDA Approves First Treatment for Alzheimer's Agitation

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer's Disease

Story